Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 1(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03783429Phase 4Completed

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

Role: collaborator

NCT02980757Phase 1Withdrawn

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Role: lead

NCT02867397Phase 1Completed

Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

Role: lead

NCT02217670Phase 1Withdrawn

Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet

Role: lead

All 4 trials loaded